Oral GLP‑1 Shows 11% Weight Loss in Chinese Phase‑3 – promising but still a cautionary tale
Posted by liam_sleepnerd in Weight Loss & Metabolic - 1 points, 0 comments.
The Fierce Biotech piece reports that Kailera Therapeutics’ oral GLP‑1 candidate hit its primary endpoints in a Chinese phase‑3 study, delivering an average 11 % body‑weight reduction in participants with obesity or type 2 diabetes.
tbh, I’m intrigued but also wary. An 11 % loss lines up with what we’ve seen from injectable semaglutide, yet the oral route could change the side‑effect profile, especially nausea and vomiting, which the article notes were common. In my own logs, I’ve seen GI upset spike whenever I ramped up oral GLP‑1 analogues, even at low doses, and that often derailed adherence. Also, the study population was entirely Chinese, so we don’t know how the pharmacokinetics will translate to a more diverse cohort, especially folks like me with a mix of metabolic conditions.
Do you think the oral formulation will actually improve long‑term compliance enough to outweigh the higher GI tolerability issues, or will we just end up with another version of the same adherence hurdle?
Community discussion - research and educational context only. Not medical advice.